Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.4952W HIGH $30.06
Volume
35.36 K
Value Traded
31.64 M
Short % Float
15.77%
-7.61%Week
-26.07%1 Month
-17.3%3 Month
-10.89%6 Month
+20.33%5 Year
+38.31%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.15 B
EPS (TTM)
-2.24
P/E Ratio
-
Ent. Value
1.67 B
Total Shares
113.59 M
Float Shares
103.00 M
Insiders
9.31%
Institutions
103.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IMNM Catalyst Timeline
Dated clinical, regulatory and corporate events for Immunome, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immunome, Inc.
183Total events
8Upcoming
43Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲IND ClearanceIM-1340IND
FDA clears IND for IM-1340 in advanced solid tumors
advanced solid tumorssource ↗
●R&D DayPresentation
Immunome management to present at H.C. Wainwright 28th Annual Global Investment Conference
▲First Patient DosedIM-3050Trial
First patient dosed in Phase 1 trial of IM-3050
FAP-expressing advanced solid tumorssource ↗
▲FDA Filing AcceptedVaregacestatFiledRegulatory Filing
FDA accepted NDA for varegacestat for desmoid tumors
desmoid tumorssource ↗
▲FDA Filing AcceptedVaregacestatFiledRegulatory Filing
FDA accepted NDA for varegacestat in adults with desmoid tumors
desmoid tumorssource ↗
▲First Patient DosedIM-3050Trial
First patient dosed in Phase 1 trial of IM-3050
FAP-expressing advanced solid tumorssource ↗
▲First Patient DosedIM-1617Trial
First patient dosed in Phase 1 trial of IM-1617
advanced solid tumorssource ↗
◆Oral PresentationPresentation
Presentation at Goldman Sachs 47th Annual Global Healthcare Conference
▲First Patient DosedIM-1617Trial
First patient dosed in Phase 1 trial of IM-1617
advanced solid tumorssource ↗
▲Oral PresentationVaregacestatFiledPresentation
Oral presentation of detailed Phase 3 RINGSIDE data at 2026 ASCO Annual Meeting
desmoid tumorssource ↗
▲Full ResultsVaregacestatFiledClinical Data
Detailed efficacy and safety results presented at ASCO 2026
desmoid tumorssource ↗
◆Oral PresentationVaregacestatFiledPresentation
Oral presentation at 2026 ASCO Annual Meeting
desmoid tumorssource ↗
●NDA SubmissionVaregacestatFiledRegulatory Filing
NDA submission for varegacestat
desmoid tumorssource ↗
▲First Patient DosedIM-1021Trial
Phase 1 trial of IM-1021 ongoing with objective responses observed
B-cell lymphomasource ↗
●NDA SubmissionVaregacestatFiledRegulatory Filing
NDA submission to FDA for varegacestat for desmoid tumors
desmoid tumorssource ↗
●Timing GuidanceVaregacestatFiledPresentation
NDA submission to FDA planned for Q2 2026
desmoid tumorssource ↗
●Trial InitiationIM-1617Trial
Plans to initiate Phase 1 trial of IM-1617 in Q2 2026
solid tumorssource ↗
●Trial InitiationIM-3050Trial
First clinical trial site initiated for Phase 1 trial of IM-3050
FAP-expressing solid tumorssource ↗
▲Oral PresentationVaregacestatFiledPresentation
Detailed Phase 3 RINGSIDE data presented in oral session at 2026 ASCO Annual Meeting
desmoid tumorssource ↗
▼Equity OfferingCorporate
Proposed public offering of $400 million common stock with underwriters' option for additional $60 million
▲Topline ReadoutVaregacestatFiledClinical Data
Positive topline results from Phase 3 RINGSIDE trial: met primary endpoint (PFS) with HR=0.16, p<0.0001
desmoid tumorssource ↗
▲Primary Endpoint MetVaregacestatFiledClinical Data
Primary endpoint of progression-free survival met with statistical significance
desmoid tumorssource ↗
●Oral PresentationVaregacestatFiledPresentation
Conference call to discuss RINGSIDE topline results
desmoid tumorssource ↗
▲Topline ReadoutVaregacestatFiledClinical Data
Positive topline results reported for Phase 3 RINGSIDE trial
desmoid tumorssource ↗
▲Primary Endpoint MetVaregacestatFiledClinical Data
Primary endpoint of PFS met with HR=0.16
desmoid tumorssource ↗
●Poster PresentationHC74Presentation
Poster presentation on HC74 at AACR-NCI-EORTC conference
▲First Patient DosedIM-1021Trial
Third cohort dosed in Phase 1 dose escalation of IM-1021
advanced B-cell lymphomas and advanced solid tumorssource ↗
▲EU Orphan DesignationVaregacestatFiledEx-US Regulatory
EMA granted Orphan Drug Designation to varegacestat
desmoid tumorssource ↗
●Oral PresentationVaregacestatFiledPresentation
Two analyses of Phase 2 RINGSIDE Part A presented at ASCO 2025
desmoid tumorssource ↗
●IND Submission177Lu-FAPIND
IND submission for 177Lu-FAP expected within 18 months post-closing
oncologysource ↗
●IND SubmissionFA-TLR7aIND
IND submission for FA-TLR7a expected within 18 months post-closing
oncologysource ↗
Past FDA Catalysts and PDUFA Decisions
How IMNM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-31 | IM-3050 (FAP-targeted radioligand) | IND Submission | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$511M
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.2x
rNPV / MCap
Top 45%
Small Cap(rank 297 of 658)
Percentile Rank
Immunome, Inc. faces pipeline headwinds (38/100), with $846M risk-adjusted pipeline value, led by IM-1021 in Solid Malignancies (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IM-1021 Small moleculeNCT06823167 | Solid Malignancies | Phase 1 | RECRUITING | 190 | Feb 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMNM program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Higgins JackOfficer (Chief Scientific Officer) | Option | 18,000 133,840 held | $0.00 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMNM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 7 % (-13.6 %) | 104.08 M | 4.91 M | -11.64% ( -647.29 K) |
IMNM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMNM ranks across every disease it competes in
Competitive Position is a premium feature
See how IMNM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMNM News
IMNM▼ -1.8%today
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. announced the granting of inducement awards on October 1, 2026, which includes non-statutory stock options for 120,900 shares and 7,200 restricted stock units. This move is part of their strategy to attract and retain talent as they continue to develop targeted cancer therapies. The awards were approved by the Compensation Committee of the Board of Directors.
Read more →IMNMImmunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Immunome, Inc. has received FDA clearance for its Investigational New Drug application for IM-1340, an antibody-drug conjugate aimed at treating advanced solid tumors. This marks a significant step for the company in its mission to develop innovative cancer therapies. IM-1340 targets a unique transport receptor, potentially offering a new treatment option for patients.
Read more →IMNMImmunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Immunome, Inc. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference scheduled for September 14, 2026. The presentation will be made by the company's management at 11:00 a.m. ET. Interested investors can access the live audio webcast through the company's website.
Read more →IMNM▲ +6.6%on this news
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Immunome, Inc. reported its financial results for Q2 2026, highlighting its ongoing commitment to developing targeted cancer therapies. CEO Clay B. Siegall emphasized the company's strategy to diversify its oncology portfolio. The report reflects Immunome's progress in creating impactful treatments for patients in need.
Read more →IMNMImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
Immunome, Inc. has announced the dosing of the first patient in its Phase 1 trial for IM-3050, a novel FAP-targeted radioligand therapy. This investigational treatment aims to target advanced solid tumors that express FAP, a protein found in a significant percentage of these tumors. The trial marks a critical step in developing targeted cancer therapies.
Read more →IMNMImmunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome, Inc. announced that the U.S. FDA has accepted its New Drug Application for varegacestat, a gamma secretase inhibitor aimed at treating adults with desmoid tumors. This acceptance marks a crucial step in the drug's development process. The FDA has set a target action date under the Prescription Drug User Fee Act.
Read more →IMNMImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Immunome has announced the dosing of the first patient in its Phase 1 trial for IM-1617, an innovative antibody-drug conjugate targeting advanced solid tumors. This development marks a significant step in evaluating the drug's efficacy and safety profile. The trial aims to assess IM-1617's potential as a first-in-class treatment option.
Read more →IMNMImmunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Immunome's announcement regarding the Phase 3 RINGSIDE data for Varegacestat is lacking in detail. The article does not provide any insights into the trial results or implications for adults with progressing desmoid tumors. This absence of information raises concerns about the transparency of the data presented at the ASCO Annual Meeting.
Read more →IMNMImmunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Immunome is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is a significant platform for companies to showcase their innovations and strategies in the healthcare sector. Further details about the presentation content or objectives were not provided.
Read more →IMNMImmunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome has released its financial results for the first quarter of 2026, along with a business update. The report highlights the company's current financial standing and strategic direction. Further details on specific financial metrics and business initiatives were not provided in the article.
Read more →IMNMImmunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome, Inc. has submitted a New Drug Application (NDA) to the FDA for varegacestat, an oral gamma secretase inhibitor aimed at treating adults with desmoid tumors. This submission is backed by positive results from the Phase 3 RINGSIDE trial, which demonstrated significant improvements in progression-free survival and tumor response rates compared to placebo. The drug was generally well tolerated, although some adverse events were reported.
Read more →IMNMImmunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
Immunome, Inc. announced that data from its Phase 3 RINGSIDE trial of varegacestat will be presented at the 2026 ASCO Annual Meeting. The trial focuses on treating progressing desmoid tumors and has shown positive topline results. The oral presentation is scheduled for May 30, 2026, with details on the trial's efficacy and safety to be shared.
Read more →IMNMImmunome Reports Full Year 2025 Financial Results and Provides Business Update
Immunome, Inc. reported its financial results for 2025, highlighting significant progress in its pipeline. The company announced positive Phase 3 results for varegacestat, supporting an NDA submission planned for Q2 2026. Additionally, Immunome is advancing its antibody-drug conjugate pipeline, with ongoing studies and multiple IND submissions expected in 2026.
Read more →IMNMImmunome to Present at Upcoming Investor Conferences
Immunome, Inc. announced that its management will present at two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and the Leerink Partners Global Healthcare Conference on March 10, 2026. Interested parties can access live webcasts of these presentations on the company's website. Immunome is dedicated to developing targeted cancer therapies.
Read more →IMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 5, 2026
Immunome, Inc. has granted inducement stock options to a new employee as part of its 2024 Inducement Plan. The Compensation Committee approved these options, which total 30,000 shares at an exercise price of $26.14. The options will vest over four years, reflecting the company's commitment to attracting talent. Immunome continues to develop innovative cancer therapies.
Read more →About Immunome, Inc.
Headquarters18702 N. CREEK PARKWAY, BOTHELL, WA, 98011
BIOPHARMAWATCH ELITE PLUS
Trade the next IMNM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime